Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$14.4 - $16.4 $783,028 - $891,782
-54,377 Reduced 51.24%
51,751 $848,000
Q1 2024

May 13, 2024

BUY
$14.56 - $16.78 $398,114 - $458,815
27,343 Added 34.71%
106,128 $1.62 Million
Q4 2023

Feb 14, 2024

BUY
$12.32 - $16.27 $452,464 - $597,532
36,726 Added 87.32%
78,785 $1.26 Million
Q3 2023

Nov 14, 2023

BUY
$12.37 - $13.89 $188,766 - $211,961
15,260 Added 56.94%
42,059 $546,000
Q2 2023

Aug 14, 2023

BUY
$11.39 - $13.72 $71,267 - $85,846
6,257 Added 30.46%
26,799 $341,000
Q1 2023

May 15, 2023

BUY
$10.73 - $13.6 $220,415 - $279,371
20,542 New
20,542 $231,000
Q3 2022

Nov 14, 2022

BUY
$11.61 - $15.22 $490,301 - $642,755
42,231 New
42,231 $490,000
Q2 2020

Aug 14, 2020

SELL
$11.49 - $15.26 $807,563 - $1.07 Million
-70,284 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$8.11 - $15.23 $16,090 - $30,216
-1,984 Reduced 2.75%
70,284 $827,000
Q4 2019

Feb 14, 2020

BUY
$10.28 - $14.38 $742,915 - $1.04 Million
72,268 New
72,268 $1.02 Million
Q3 2019

Nov 14, 2019

SELL
$10.05 - $14.55 $1.08 Million - $1.56 Million
-107,263 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$13.1 - $14.95 $1.41 Million - $1.6 Million
107,263 New
107,263 $1.56 Million
Q1 2019

May 15, 2019

SELL
$13.69 - $20.06 $429,633 - $629,542
-31,383 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$13.96 - $18.26 $438,106 - $573,053
31,383 New
31,383 $548,000
Q4 2017

Feb 14, 2018

SELL
$11.73 - $14.75 $195,668 - $246,044
-16,681 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$12.06 - $14.12 $201,172 - $235,535
16,681
16,681 $236,000

Others Institutions Holding INVA

About Innoviva, Inc.


  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.33B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.